AliM. Pulmonary drug delivery. In: KulkarniK, editor. Handbook of non-invasive drug delivery systems. Amsterdam: Elsevier; 2009:209–246.
2.
HindsWC. Aerosol technology: properties, behavior, and measurement of airborne particles. New York: Wiley-Interscience; 1999; 235.
3.
International Commission on Radiological Protection. Human respiratory tract model for radiological protection. New York: Elsevier; 1994.
4.
YehHC, SchumGM. Models of human lung airways and their application to inhaled particle deposition. Bull Math Biol, 1980; 42(3):461–480.
5.
MartonenTB, SchroeterJD, FlemingJS. 3D in-silico modeling of the human respiratory system for inhaled drug delivery and imaging analysis. J Pharm Sci, 2007; 96(3):603–617.
6.
AliM, ReddyRN, MazumderMK. Electrostatic charge effect on respirable aerosol particle deposition in a cadaver based throat cast replica. J Electrostat, 2008; 66(7-8):401–406.
AzhdarzadehaM, OlfertaJS, VehringR, FinlayWH. Effect of induced charge on deposition of uniformly charged particles in a pediatric oral-extrathoracic airway. Aerosol Sci Tech, 2014; 48(5):508–514.
9.
AsgharianB, HofmannW, BergmannR. Particle deposition in a multiple-path model of the human lung. Aerosol Sci Technol, 2001; 34(4):332–339.
10.
KleinstreuerC, ZhangZ, DonohueJF. Targeted drug-aerosol delivery in the human respiratory system. Ann Rev Biomed Eng, 2008; 10(1):195–220.
11.
ChengYS. Mechanisms of pharmaceutical aerosol deposition in the respiratory tract. AAPS Pharm Sci Tech, 2014; 15(3):630–640.
12.
PattonJS, ByronPR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov, 2007; 6(1):67–74.
13.
DavisME, ChenZG, ShinDM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov, 2008; 7(9):771–782.
14.
PengC, ChowAHL, ChanCK. Study of the hygroscopic properties of selected pharmaceutical aerosols using single particle levitation. Pharma Res, 2000; 17(9):1104–1109.
15.
OnischukAA, TolstikovaTG, SorokinaIV, ZhukovaNA, BaklanovAM, KarasevVV, et al. Anti-inflammatory effect from indomethacin nanoparticles inhaled by male mice. J Aerosol Med Pulm Drug Deliv, 2008; 21(3):231–243.
16.
AtkinsPJ. Next generation technology for pulmonary drug delivery. Drug Deliv Technol, 2005; 5(6):74–75.
17.
MorozovVN, KanevIL, MikheevAY, ShlyapnikovaEA, ShlyapnikovEM, NikitinMP, et al. Generation and delivery of nanoaerosols from biological and biologically active substances. J Aerosol Sci, 2014; 69(3):48–61.
18.
GolshahiL, TianG, AzimiM, SonYJ, WalengaR, LongestPW, HindleM. The use of condensational growth methods for efficient drug delivery to the lungs during noninvasive ventilation high flow therapy. Pharm Res, 2013; 30(11):2917–2930.
19.
AriA, HarwoodR, SheardM, DaileyP, FinkJB. In vitro comparison of heliox and oxygen in aerosol delivery using pediatric high flow nasal cannula. Pediatr Pulmonol, 2011; 46(8):795–801.
20.
RubinBK. Pediatric aerosol therapy: new devices and new drugs. Respir Care, 2011; 56(9):1411–1421.
21.
DhandR. Aerosol therapy in patients receiving noninvasive positive pressure ventilation. J Aerosol Med Pulm Drug Deliv, 2012; 25(2):63–78.
22.
GolshahiL, LongestPW, Azimi, SyedA, HindleM. Intermittent aerosol delivery to the lungs during high-flow nasal cannula therapy. Respir Care, 2014; 59(10):1476–1486.